World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival2011 · 919 citations
2. 2Bispecific digoxigenin-binding antibodies for targeted payload delivery2011 · 70 citations
3. 3Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)2009 · 433 citations
4. 4B lymphocytes: how they develop and function2008 · 1,396 citations
5. 5Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing1999 · 205 citations